NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis $49.14 +0.79 (+1.63%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$48.50▼$49.4950-Day Range$45.03▼$50.3352-Week Range$18.62▼$50.66Volume4,552 shsAverage Volume57,424 shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/APrice Target$54.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Belite Bio alerts: Email Address Belite Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside11.4% Upside$54.75 Price TargetShort InterestBearish0.96% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.08) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector858th out of 936 stocksPharmaceutical Preparations Industry402nd out of 436 stocks 2.5 Analyst's Opinion Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 3 research reports in the past 90 days.Read more about Belite Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.96% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Belite Bio has recently increased by 27.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLTE. Previous Next 1.3 News and Social Media Coverage News SentimentBelite Bio has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Belite Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BLTE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($1.08) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -41.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -41.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 14.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Belite Bio Stock (NASDAQ:BLTE)Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Read More BLTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLTE Stock News HeadlinesJuly 16, 2024 | americanbankingnews.comBelite Bio, Inc (NASDAQ:BLTE) Given Consensus Recommendation of "Buy" by BrokeragesJune 12, 2024 | globenewswire.comBelite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in JapanJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. on Strong Clinical Trials and Solid Financial FootingMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Strong Financials and Promising Stargardt Disease Drug ProspectsMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Promising Tinlarebant Trials and Potential Stargardt Disease TreatmentMay 14, 2024 | seekingalpha.comBelite Bio, Inc 2024 Q1 - Results - Earnings Call PresentationMay 14, 2024 | finance.yahoo.comBelite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor ConferenceJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.May 14, 2024 | investorplace.comBLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024May 14, 2024 | globenewswire.comBelite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor ConferenceMay 14, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comBelite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comBelite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 8, 2024 | globenewswire.comBelite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comBelite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantMay 6, 2024 | globenewswire.comBelite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingMay 2, 2024 | seekingalpha.comBLTE Belite Bio, IncSee More Headlines Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$54.75 High Stock Price Target$60.00 Low Stock Price Target$43.00 Potential Upside/Downside+12.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.15% Return on Assets-41.53% Debt Debt-to-Equity RatioN/A Current Ratio24.76 Quick Ratio24.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book14.79Miscellaneous Outstanding Shares29,790,000Free Float25,834,000Market Cap$1.44 billion OptionableNot Optionable Beta-1.47 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Yu-Hsin Lin M.B.A. (Age 45)Ph.D., Chairman of the Board of Directors & CEO Mr. Hao-Yuan Chuang C.F.A. (Age 39)F.R.M., M.B.A., CFO & Director Dr. Nathan L. Mata Ph.D. (Age 57)Chief Scientific Officer Key CompetitorsViking TherapeuticsNASDAQ:VKTXOrganon & Co.NYSE:OGNNuvalentNASDAQ:NUVLBridgeBio PharmaNASDAQ:BBIOApellis PharmaceuticalsNASDAQ:APLSView All Competitors BLTE Stock Analysis - Frequently Asked Questions How have BLTE shares performed this year? Belite Bio's stock was trading at $45.75 at the beginning of 2024. Since then, BLTE shares have increased by 7.4% and is now trading at $49.14. View the best growth stocks for 2024 here. How were Belite Bio's earnings last quarter? Belite Bio, Inc (NASDAQ:BLTE) announced its quarterly earnings results on Monday, May, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.07. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLTE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLTE Stock Alerts